Screening for prostate cancer with prostate-specific antigen: beware the biases (Q34453090)

2 August 2017

0 references

1 reference

title

Screening for prostate cancer with prostate-specific antigen: beware the biases (English)

1 reference

2 August 2017

1 reference

1 reference

Peter S Bunting

1

1 reference

2 August 2017

publication date

1 January 2002

1 reference

2 August 2017

number of pages

27

1 reference

inferred from page(s)

published in

Clinica Chimica Acta

1 reference

2 August 2017

volume

315

1 reference

2 August 2017

issue

1-2

1 reference

2 August 2017

page(s)

71-97

1 reference

Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part II: Early detection strategies

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Diagnosis and management of early prostate cancer. Report of a British association of urological surgeons working party

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

American Cancer Society guideline for the early detection of prostate cancer: update 1997.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

PSA screening: a public health dilemma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Ethics of a prostate cancer screening trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Prostate cancer screening in the midst of controversy: Canadian men's knowledge, beliefs, utilization, and future intentions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Rationale for randomised trials of prostate cancer screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Cancer of the prostate: a nutritional disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Diet, androgens, oxidative stress and prostate cancer susceptibility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Screening for prostate cancer. The challenge of promoting informed decision making in the absence of definitive evidence of effectiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Family history facilitates the early diagnosis of prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Familial prostate cancer: a different disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Age-specific reference ranges for serum prostate-specific antigen in black men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Racial differences in operating characteristics of prostate cancer screening tests

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Correlation of pathologic findings with progression after radical retropubic prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Trends in patterns of care for prostatic cancer, 1974-1983: results of surveys by the American College of Surgeons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Controversies in prostate cancer screening. Analogies to the early lung cancer screening debate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Cancer screening. Degrees of proof and practical application

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Appraising organised screening programmes for testing for genetic susceptibility to cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Prostate cancer screening: promise and peril--a review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Are increasing 5-year survival rates evidence of success against cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Impact of prostate-specific antigen screening on the natural history of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Analysis of recent trends in prostate cancer incidence and mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Early detection of prostate cancer. Part I: Prior probability and effectiveness of tests. The American College of Physicians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Screening for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Progress and problems in screening for carcinoma of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Evaluation of annual examinations in the detection of cancer. Special reference to cancer of the gastrointestinal tract, prostate, breast, and female generative tract.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Prostate cancer: comparison of transrectal US and digital rectal examination for screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

A screening study of prostate cancer in high risk families

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change. Data from the American Cancer Society National Prostate Cancer Detection Project

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

An evaluation of serial digital rectal examinations in screening for prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Screening for carcinoma of the prostate. Rectal examination, and enzymatic and radioimmunologic measurements of serum acid phosphatase compared

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Accuracy of Digital Rectal Examination and Transrectal Ultrasonography in Localizing Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Is there still a role for prostatic acid phosphatase? CSCC Position Statement. Canadian Society of Clinical Chemists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

The use of percent free prostate specific antigen for staging clinically localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

An evaluation of prostate-specific antigen as a screening test for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Serum prostate-specific antigen and prostate pathology in men having simple prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Early detection program for prostate cancer: results and identification of high-risk patient population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Clinical application of transrectal ultrasonography and prostate specific antigen in the search for prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

The use of prostate-specific antigen and free/total prostate-specific antigen in the diagnosis of localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Second Stanford Conference on International Standardization of Prostate-Specific Antigen Immunoassays: September 1 and 2, 1994.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Prostate-specific antigen testing for early diagnosis of prostate cancer: formulation of guidelines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Etiology and diagnosis of prostate cancer: what's new? A review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

The new human kallikrein gene family: implications in carcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

A guide to the interpretation of serum prostate specific antigen levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Free/total PSA ratio improves differentiation of benign and malignant disease of the prostate: critical analysis of two different test populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Free and total prostate-specific antigen in a screened population.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

The stability of free and bound prostate-specific antigen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Longitudinal screening for prostate cancer with prostate-specific antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Diagnosis of Prostatic Carcinoma: The Yield of Serum Prostate Specific Antigen, Digital Rectal Examination and Transrectal Ultrasonography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Screening for prostate cancer: an analysis of the early experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Comparison of pathologic characteristics of T1c and non-T1c cancers detected in a population-based screening study, the European Randomized Study of Screening for Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Histopathological prostate cancer characteristics at radical prostatectomy after population based screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

PSA screening--current controversy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Positive and negative biopsies in the pre-prostate specific antigen and prostate specific antigen eras, 1980 to 1997.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Screening for prostate cancer--necessity or nonsense?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Heterogeneity of prostate cancer in radical prostatectomy specimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Positive prostate biopsy rate consistently increases with age at the same prostate-specific antigen level in patients with normal digital rectal examination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Staging of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Tumor volume and prostate specific antigen: implications for early detection and defining a window of curability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Molecular and cellular biology of the prostate: is it clinically relevant?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Tumour-suppressor genes in prostatic oncogenesis: a positional approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Identification of genetic markers for prostatic cancer progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Genomewide scan for prostate cancer-aggressiveness loci.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Combined analysis of hereditary prostate cancer linkage to 1q24-25: results from 772 hereditary prostate cancer families from the International Consortium for Prostate Cancer Genetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Prostate-specific membrane antigen (PSMA): current benefits and future value

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Detection of extraprostatic prostate cells utilizing reverse transcription-polymerase chain reaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Population-based study of long-term survival in patients with clinically localised prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Screening for prostate cancer. A decision analytic view

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Quality-of-life outcomes for men with prostate carcinoma detected by screening.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Prostate cancer: A challenge for screening.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancer in a population based screening study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Prostate carcinoma trends in three counties in Sweden 1987-1996: results from a population-based national cancer register. South-East Region Prostate Cancer Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Prostate cancer screening in the Tyrol, Austria: experience and results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Downward trend in prostate cancer mortality in Quebec and Canada.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Prostate-specific antigen utilization in Ontario: extent of testing in patients with and without cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Cancer surveillance series: interpreting trends in prostate cancer--part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

PSA screening for prostate cancer: the current controversy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Prostate cancer screening. Appropriate choices? Investigators of the American Cancer Society National Prostate Cancer Detection Project

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Early detection of prostate cancer. Part II: Estimating the risks, benefits, and costs. American College of Physicians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Attitudes and practices of primary care physicians for prostate cancer screening.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Attitudes of European urologists to early prostatic carcinoma, II. Attitude to therapy and to screening examinations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Decision aids for patients facing health treatment or screening decisions: systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

What questions do patients with curable prostate cancer want answered?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

The impact of informed consent on patient interest in prostate-specific antigen screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

A randomized controlled trial of shared decision making for prostate cancer screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

The Use of Prostate Specific Antigen for Prostate Cancer Screening: A Managed Care Perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Impact of routine screening for adenocarcinoma of the prostate on stage distribution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

7 January 2021

inferred from DOI database lookup

The relationship of prostate-specific antigen to digital rectal examination and transrectal ultrasonography. Findings of the American Cancer Society National Prostate Cancer Detection Project

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

7 January 2021

inferred from DOI database lookup

Systematic sextant biopsies in 651 patients referred for prostate evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1016/S0009-8981(01)00717-3

1 reference

2 August 2017

1 reference